Immunochemical Characterization of Two Activator Proteins Stimulating Enzymic Sphingomyelin Degradation in vitro Absence of One of them in a Human Gaucher Disease Variant
- 1 January 1986
- journal article
- research article
- Published by Walter de Gruyter GmbH in Biological Chemistry Hoppe-Seyler
- Vol. 367 (2), 879-890
- https://doi.org/10.1515/bchm3.1986.367.2.879
Abstract
Two nonenzymic activator proteins shown previously to strongly stimulate enzymic sphingomyelin degradation in vitro were purified from human Gaucher type 1 and control spleen. Activator A1 (molecular mass 65000 Da) had affinity for ConA-Sepharose, while activator A2 (molecular mass 3500 Da) did not. Monospecific antibodies to each activator protein were prepared in rabbits by immunization with protein purified from type 1 Gaucher spleen. A1 and A2 activators from Gaucher type 1 spleen were shown to be immunochemically identical to A1 and A2 activators from control spleen. However, A1 and A2 activators, whether isolated from Gaucher type 1 or control spleen, were shown to be distinct proteins. Immunochemical examination of all collected fractions during the purification revealed the existence of a third activator (molecular mass 6000 Da), which was antigenically identical to A1 activator but had no affinity for ConA-Sepharose. The two forms of A1 activator showed similar mobility on immunoelectrophoresis differing from that of A2 activator. Fibroblast extracts from controls and patients with different variants of Gaucher disease were investigated using immunodiffusion against antisera to A1 or A2 activator. In contrast to normal and Gaucher (types 1, 2 and 3) cell extracts, those of a Gaucher patient with normal glucosylceramidase activity had no visible precipitin line towards the antiserum against the two forms of A1 activator. The lack of crossreacting material to antibodies against A1 activator was confirmed by radial immunodiffusion and rocket immunoelectrophoresis. A1 activator stimulated the basal glucosylceramidase activity 5-6-fold in fibroblasts from this patient, whereas the normal effect was only a 1.2-1.5-fold stimulation. The immunological results together with the biochemical data provide evidence for the lack of an activator protein in a variant form of human Gaucher disease for the first time.This publication has 29 references indexed in Scilit:
- An endogenous activator protein in human placenta for enzymatic degradation of glucosylceramideBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1985
- Isolation of two Forms of an Activator Protein for the Enzymic Sphingomyelin Degradation from Human Gaucher SpleenBiological Chemistry Hoppe-Seyler, 1985
- The cohydrolases in human spleen that stimulate glucosyl ceramide β-glucosidaseBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1983
- A protein activator of galactosylceramide β-galactosidaseBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1982
- Mechanism of activation of glucocerebrosidase by CO-β-glucosidase (glucosidase activator protein)Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981
- Niemann-Pick Disease, Type C: Evidence for the Deficiency of an Activating Factor Stimulating Sphingomyelin and Glucocerebroside DegradationHoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1980
- Purification and Characterization of an Activator Protein for the Degradation of Glycolipids GM2and GA2by Hexosaminidase AHoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1979
- The Activator of Cerebroside Sulphatase. Purification from Human Liver and Identification as a ProteinHoppe-Seyler´s Zeitschrift Für Physiologische Chemie, 1975
- Maturation of the head of bacteriophage T4Journal of Molecular Biology, 1973
- Une micro-méthode de l’immuno-électrophorèseInternational Archives of Allergy and Immunology, 1955